Search

Displaying results 4401 - 4410 of 10000 in total
  1. Drug

    TAS-108

    go.drugbank.com/drugs/DB05966
    Investigational

  2. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456].

  3. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals. … PW2101 is a beta blocker intended for the treatment of hypertension and angina.

  4. Drug

    Regramostim

    go.drugbank.com/drugs/DB05386
    Investigational

    Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. … Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.

  5. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

  6. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  7. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

  8. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  9. Drug

    GTI 2040

    go.drugbank.com/drugs/DB05801
    Investigational

    GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.

  10. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]